• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aquestive Therapeutics Inc.

    4/1/24 6:21:14 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AQST alert in real time by email
    SC 13G 1 tm2410360d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Aquestive Therapeutics, Inc.

     

    (Name of Issuer)

     

    Common stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    03843E104

     

    (CUSIP Number)

     

    March 22, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

     

     

     

     

    CUSIP No. 03843E104 Page 2 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,555,555 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,555,555 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,555,555 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,210,555 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 121,111 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,223,889 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based on 85,199,752 shares of common stock outstanding as of March 22, 2024 as disclosed in the Issuer’s prospectus supplement dated March 19, 2024 filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2024.

     

     

     

     

     

    CUSIP No. 03843E104 Page 3 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,555,555 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,555,555 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,555,555 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

       

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,210,555 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 121,111 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,223,889 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based on 85,199,752 shares of common stock outstanding as of March 22, 2024 as disclosed in the Issuer’s prospectus supplement dated March 19, 2024 filed with the SEC on March 21, 2024.

     

     

     

     

     

    CUSIP No. 03843E104 Page 4 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,555,555 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,555,555 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,555,555 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2) Consists of (i) 1,210,555 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 121,111 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,223,889 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based on 85,199,752 shares of common stock outstanding as of March 22, 2024 as disclosed in the Issuer’s prospectus supplement dated March 19, 2024 filed with the SEC on March 21, 2024.

      

     

     

     

     

    CUSIP No. 03843E104 Page 5 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,555,555 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,555,555 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,555,555 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,210,555 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 121,111 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,223,889 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based on 85,199,752 shares of common stock outstanding as of March 22, 2024 as disclosed in the Issuer’s prospectus supplement dated March 19, 2024 filed with the SEC on March 21, 2024.

     

     

     

     

     

    CUSIP No. 03843E104 Page 6 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,555,555 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,555,555 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,555,555 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,210,555 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 121,111 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,223,889 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based on 85,199,752 shares of common stock outstanding as of March 22, 2024 as disclosed in the Issuer’s prospectus supplement dated March 19, 2024 filed with the SEC on March 21, 2024.

     

     

     

     

     

    CUSIP No. 03843E104 Page 7 of 17

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,555,555 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,555,555 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,555,555 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 1,210,555 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 121,111 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,223,889 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based on 85,199,752 shares of common stock outstanding as of March 22, 2024 as disclosed in the Issuer’s prospectus supplement dated March 19, 2024 filed with the SEC on March 21, 2024.

     

     

     

     

     

    CUSIP No. 03843E104 Page 8 of 17

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,555,555 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,555,555 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,555,555 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 1,210,555 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 121,111 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,223,889 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based on 85,199,752 shares of common stock outstanding as of March 22, 2024 as disclosed in the Issuer’s prospectus supplement dated March 19, 2024 filed with the SEC on March 21, 2024.

     

     

     

     

     

    CUSIP No. 03843E104 Page 9 of 17

     

    Item 1.
      (a)

    Name of Issuer

     

    Aquestive Therapeutics, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    30 Technology Drive, Warren, NJ 07059

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence
             
        New York Office: Palo Alto Office:  
             
        7 Bryant Park 3340 Hillview Avenue  
        23rd Floor Palo Alto, CA 94304  
        New York, NY 10018    

     
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.001 par value

     
      (e)

    CUSIP Number

     

    03843E104

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

     

     

     

    CUSIP No. 03843E104 Page 10 of 17

     

    Item 4.   Ownership  
           
      (a) Amount beneficially owned:  

     

      Venrock Healthcare Capital Partners III, L.P.   5,555,555(1)
      VHCP Co-Investment Holdings III, LLC   5,555,555(1)
      Venrock Healthcare Capital Partners EG, L.P.   5,555,555(1)
      VHCP Management III, LLC   5,555,555(1)
      VHCP Management EG, LLC   5,555,555(1)
      Nimish Shah   5,555,555(1)
      Bong Koh   5,555,555(1)

     

      (b) Percent of class:  

     

      Venrock Healthcare Capital Partners III, L.P.   6.5 % (2)
      VHCP Co-Investment Holdings III, LLC   6.5 % (2)
      Venrock Healthcare Capital Partners EG, L.P.   6.5 % (2)
      VHCP Management III, LLC   6.5 % (2)
      VHCP Management EG, LLC   6.5 % (2)
      Nimish Shah   6.5 % (2)
      Bong Koh   6.5 % (2)

     

      (c) Number of shares as to which the person has:  

     

        (i)     Sole power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   0
      VHCP Co-Investment Holdings III, LLC   0
      Venrock Healthcare Capital Partners EG, L.P.   0
      VHCP Management III, LLC   0
      VHCP Management EG, LLC   0
      Nimish Shah   0
      Bong Koh   0

     

        (ii)     Shared power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   5,555,555(1)
      VHCP Co-Investment Holdings III, LLC   5,555,555(1)
      Venrock Healthcare Capital Partners EG, L.P.   5,555,555(1)
      VHCP Management III, LLC   5,555,555(1)
      VHCP Management EG, LLC   5,555,555(1)
      Nimish Shah   5,555,555(1)
      Bong Koh   5,555,555(1)

     

     

     

     

    CUSIP No. 03843E104 Page 11 of 17

     

        (iii)   Sole power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.   0
      VHCP Co-Investment Holdings III, LLC   0
      Venrock Healthcare Capital Partners EG, L.P.   0
      VHCP Management III, LLC   0
      VHCP Management EG, LLC   0
      Nimish Shah   0
      Bong Koh   0

     

        (iv)   Shared power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.   5,555,555(1)
      VHCP Co-Investment Holdings III, LLC   5,555,555(1)
      Venrock Healthcare Capital Partners EG, L.P.   5,555,555(1)
      VHCP Management III, LLC   5,555,555(1)
      VHCP Management EG, LLC   5,555,555(1)
      Nimish Shah   5,555,555(1)
      Bong Koh   5,555,555(1)

     

    (1)Consists of (i) 1,210,555 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 121,111 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,223,889 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

        VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    (2)This percentage is calculated based on 85,199,752 shares of common stock outstanding as of March 22, 2024 as disclosed in the Issuer’s prospectus supplement dated March 19, 2024 filed with the SEC on March 21, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ☐
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable

     

    Item 8. Identification and Classification of Members of the Group
       
      Not applicable

     

     

     

     

    CUSIP No. 03843E104 Page 12 of 17

     

    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 03843E104 Page 13 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 1, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

     

     

    CUSIP No. 03843E104 Page 14 of 17

     

    EXHIBITS
     
    A:  Joint Filing Agreement
     
    B: Power of Attorney for Nimish Shah
     
    C: Power of Attorney for Bong Koh

     

     

     

     

    CUSIP No. 03843E104 Page 15 of 17

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Aquestive Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 1st day of April, 2024.

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

     

     

    CUSIP No. 03843E104 Page 16 of 17

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of April, 2024.

     

    /s/ Nimish Shah  

     

     

     

     

    CUSIP No. 03843E104 Page 17 of 17

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of April, 2024.

     

    /s/ Bong Koh  

     

     

    Get the next $AQST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AQST

    DatePrice TargetRatingAnalyst
    6/2/2025$7.00Outperform
    Oppenheimer
    12/17/2024$17.00Overweight
    Cantor Fitzgerald
    5/10/2024$8.00Outperform
    Leerink Partners
    4/11/2024$10.00Overweight
    Piper Sandler
    3/28/2024$7.00Outperform
    Raymond James
    More analyst ratings

    $AQST
    SEC Filings

    View All

    Aquestive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    8/14/25 9:37:47 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Aquestive Therapeutics Inc.

    424B5 - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    8/14/25 5:29:02 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    8/14/25 6:26:15 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Korczynski Sherry was granted 25,000 shares, increasing direct ownership by 16% to 181,858 units (SEC Form 4)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    8/15/25 8:41:12 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kraus Carl N covered exercise/tax liability with 10,819 shares, decreasing direct ownership by 3% to 302,747 units (SEC Form 4)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    8/12/25 10:11:01 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Brown Gregory B

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    6/12/25 2:13:31 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Aquestive Therapeutics with a new price target

    Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00

    6/2/25 8:47:02 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Aquestive Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $17.00

    12/17/24 7:27:23 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Aquestive Therapeutics with a new price target

    Leerink Partners initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/10/24 7:29:48 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

    WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be $85 million. The Company intends to use the net proceeds received from the offering, together with the Compan

    8/14/25 6:28:38 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

    Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company's balance sheet in advance of potential commercialization of Anaphylm for the emergency treatment of allergic reactions, including anaphylaxis WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP ("RTW"), su

    8/14/25 6:00:30 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany to host investor call on August 12, 2025, at 8:00am ET WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update. "The sec

    8/11/25 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Financials

    Live finance-specific insights

    View All

    Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany to host investor call on August 12, 2025, at 8:00am ET WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update. "The sec

    8/11/25 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

    WARREN, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2025 and provide an update on recent developments in its business after market close on Monday, August 11, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 12, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast

    8/4/25 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

    Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2025, and provided a strategic business update. "In the firs

    5/12/25 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aquestive Therapeutics Inc.

    SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    11/14/24 3:47:19 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aquestive Therapeutics Inc.

    SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    4/1/24 6:21:14 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aquestive Therapeutics Inc.

    SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    2/14/24 3:24:42 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Leadership Updates

    Live Leadership Updates

    View All

    Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

    WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public

    6/18/24 8:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

    WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

    4/1/24 8:00:00 AM ET
    $AQST
    $EBS
    $GMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

    Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company. NDA Filing for Libervant for Pediatric PopulationAquestive submitted a N

    6/29/23 8:42:55 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care